Over the weekends I try to catch up on more diverse reading and sometimes come up with a list of stuff I want to get to during this time, but I also put together weekend reads usually on Fridays as a kind of TGIF on The Niche for the wider audience here. So here’s the […]
TGIF weekend reads: senolytics, new CRISPR, stem cells, & 3 wacky things Read More »
Heritable CRISPR to be tried in humans sooner or later…or never? Will someone somewhere in the world try to use CRISPR gene editing or related technology to introduce heritable genetic changes into actual human beings in the next decade? I’m not talking about gene editing viable human embryos just for research which is already ongoing,
Poll: heritable CRISPR tried in humans in next 10 years? Read More »
Could potential associated cancer risks claw into CRISPR’s potential? The short answer from both previous and new data is that while CRISPR gene editing impacts the P53 pathway, which is involved in cancer along with having many other functions, this news is neither too surprising nor a fatal flaw, but some caution is warranted. CRISPR
Could Cancer Risk Claw CRISPR’s Potential? Some Balanced Perspectives Read More »
By Anna Everette The title of this article is partially borrowed from a fascinating Lightning Presentation delivered by John Doench of Broad Institute at CRISPRcon this year. In his talk, Mr. Doench pointed out how we’ve been looking up to this promising technology for a while now, hoping it will deliver the anticipated results (see
The Hope of CRISPRcon: Year 2, Guest Post by Anna Everette Read More »
Some in CRISPR-Cas9-land who are focused on potential future clinical applications are kind of rejoicing or at least sighing a breath of relief. This upbeat swing in the atmosphere (from investors especially) was sparked by retraction of that paper, the one initially reporting tons of supposed off-target CRISPR-Cas9 activity in mice, which turned out to be a “nothing
Analysis: human immunity to Cas9 bigger #CRISPR therapeutic hurdle than off-targets? Read More »
There are many genomics meetings out there these days, but The Future of Genomic Medicine meeting (#FOGM18) at Scripps in La Jolla is one of my favorites. This meeting is uniquely empowering. The people and the talks combine for a one-of-a-kind experience. The venue doesn’t hurt either at the Scripps Seaside Forum. The evening before the meeting
Highlights FOGM18 Day 1: Data from Ancient Dirt, Genomics Dilemmas, CAR-T, CRISPR Read More »
My first job in science was as a lab technician at UCSD School of Medicine and a big part of that job was growing cells called HUVECs or human umbilical vein endothelial cells. We isolated and grew the HUVECs from umbilical cords that we retrieved from the maternity ward of the UCSD hospital, which first
Why we shouldn’t view the human embryo as a gizmo even in the CRISPR era Read More »
CRISPR and IPS cells are two of my favorite things so when they come together as in a cool, new paper from Sheng Ding’s lab, I’m excited to read it and curious as to what the scoop is. Since 2006-2007 when mouse and human reprogramming were first reported, many different methods have been explored to
CRISPR to make IPS cells: review of new Ding lab paper Read More »
The news that CRISPR-Cas9 gene editing in its current form may not work in a substantial fraction of people due to many of us having immunity to Cas9 came as a shock to many, but if you think about it, maybe it’s not so surprising. I don’t see it as the end of the world. A (preprint) from
Keep calm & CRISPR on: perspectives on report of human Cas9 immunity Read More »
Human germline CRISPR raises major bioethical considerations, but what about technical issues? Setting aside the many ethical issue about the general idea of human modification itself, could this really work? Yes in theory it could, but there are some very tough technological challenges that could and likely would cause failures or unacceptable outcomes at many steps
7 tech hurdles to human germline CRISPR Read More »